Rallybio (RLYB) Competitors $0.95 -0.03 (-2.68%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RLYB vs. TSVT, CKPT, NKTX, ZURA, CDTX, VTYX, SCPH, TCRX, NBTX, and FTLFShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include 2seventy bio (TSVT), Checkpoint Therapeutics (CKPT), Nkarta (NKTX), Zura Bio (ZURA), Cidara Therapeutics (CDTX), Ventyx Biosciences (VTYX), scPharmaceuticals (SCPH), TScan Therapeutics (TCRX), Nanobiotix (NBTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. 2seventy bio Checkpoint Therapeutics Nkarta Zura Bio Cidara Therapeutics Ventyx Biosciences scPharmaceuticals TScan Therapeutics Nanobiotix FitLife Brands 2seventy bio (NASDAQ:TSVT) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends. Is TSVT or RLYB more profitable? Rallybio has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% Rallybio N/A -77.39%-69.33% Does the media refer more to TSVT or RLYB? In the previous week, 2seventy bio had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for 2seventy bio and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 beat 2seventy bio's score of -1.00 indicating that Rallybio is being referred to more favorably in the news media. Company Overall Sentiment 2seventy bio Negative Rallybio Neutral Which has preferable earnings and valuation, TSVT or RLYB? Rallybio has lower revenue, but higher earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$45.62M3.55-$217.57M-$1.86-1.69Rallybio$598K65.91-$74.56M-$1.60-0.59 Do insiders & institutionals believe in TSVT or RLYB? 93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by company insiders. Comparatively, 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in TSVT or RLYB? Rallybio received 16 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 77.36% of users gave Rallybio an outperform vote while only 56.82% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2556.82% Underperform Votes1943.18% RallybioOutperform Votes4177.36% Underperform Votes1222.64% Which has more volatility and risk, TSVT or RLYB? 2seventy bio has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.55, suggesting that its stock price is 255% less volatile than the S&P 500. Do analysts rate TSVT or RLYB? 2seventy bio currently has a consensus target price of $9.00, suggesting a potential upside of 186.62%. Rallybio has a consensus target price of $9.75, suggesting a potential upside of 926.32%. Given Rallybio's stronger consensus rating and higher possible upside, analysts plainly believe Rallybio is more favorable than 2seventy bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryRallybio beats 2seventy bio on 11 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.41M$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio-0.5910.5999.0517.15Price / Sales65.91195.041,121.17116.80Price / CashN/A57.1641.5237.88Price / Book0.345.104.754.78Net Income-$74.56M$151.51M$119.33M$225.60M7 Day Performance-12.04%-2.13%-1.86%-1.23%1 Month Performance-3.90%-3.14%11.40%3.07%1 Year Performance-63.60%11.53%30.26%16.48% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.7025 of 5 stars$0.95-2.7%$9.75+926.3%-65.5%$39.41M$598,000.00-0.5940TSVT2seventy bio2.2166 of 5 stars$3.27flat$9.00+175.2%-7.1%$168.70M$100.39M-1.76440Positive NewsCKPTCheckpoint Therapeutics3.918 of 5 stars$3.41-7.1%$10.33+203.0%+113.1%$166.51M$100,000.00-1.8310Insider TradeNews CoverageHigh Trading VolumeNKTXNkarta2.8024 of 5 stars$2.34flat$15.00+541.0%-35.4%$165.13MN/A-1.24140ZURAZura Bio3.1928 of 5 stars$2.51+10.1%$15.80+529.5%-52.8%$163.88MN/A0.003CDTXCidara Therapeutics3.6778 of 5 stars$23.00+0.5%$32.20+40.0%+54.8%$162.15M$63.90M-0.9090VTYXVentyx Biosciences2.9178 of 5 stars$2.29+0.4%$10.00+336.7%+7.7%$161.93MN/A-0.9773Gap DownSCPHscPharmaceuticals3.2504 of 5 stars$3.22+0.9%$15.00+365.8%-43.6%$161.13M$13.59M-1.6830TCRXTScan Therapeutics2.184 of 5 stars$3.01+5.6%$11.25+273.8%-38.6%$160.64M$21.05M-2.69100NBTXNanobiotix2.0865 of 5 stars$3.35+0.6%$12.00+258.2%-53.3%$157.90M$36.22M0.00100News CoverageGap UpFTLFFitLife Brands3.9622 of 5 stars$33.75-0.7%$40.00+18.5%+48.0%$155.18M$62.76M19.8220 Related Companies and Tools Related Companies 2seventy bio Alternatives Checkpoint Therapeutics Alternatives Nkarta Alternatives Zura Bio Alternatives Cidara Therapeutics Alternatives Ventyx Biosciences Alternatives scPharmaceuticals Alternatives TScan Therapeutics Alternatives Nanobiotix Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLYB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
